A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme.

Trial Profile

A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Carboplatin; Carmustine; Cisplatin; Lomustine; Nimustine; Procarbazine; Temozolomide; Vincristine; XR 311
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Xenova Group
  • Most Recent Events

    • 13 Oct 2009 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top